Michael Kraut

6.6k total citations
58 papers, 1.9k citations indexed

About

Michael Kraut is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michael Kraut has authored 58 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Michael Kraut's work include Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (18 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Michael Kraut is often cited by papers focused on Lung Cancer Research Studies (19 papers), Lung Cancer Treatments and Mutations (18 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Michael Kraut collaborates with scholars based in United States, Germany and Canada. Michael Kraut's co-authors include Robert B. Livingston, Frances A. Shepherd, David Gandara, Valerie W. Rusch, Timothy Winton, Mark B. Hazuka, David H. Johnson, Dorothy J. Giroux, Claude Deschamps and John Crowley and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Cancer.

In The Last Decade

Michael Kraut

58 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Kraut United States 24 1.0k 832 489 254 183 58 1.9k
J Maestre Spain 14 1.6k 1.6× 1.1k 1.3× 706 1.4× 382 1.5× 228 1.2× 26 2.5k
Hiroyuki Yamaguchi Japan 26 685 0.7× 927 1.1× 599 1.2× 518 2.0× 242 1.3× 156 2.0k
Makoto Kodaira Japan 22 643 0.6× 855 1.0× 627 1.3× 320 1.3× 159 0.9× 70 2.0k
T V Colby United States 13 993 1.0× 665 0.8× 390 0.8× 240 0.9× 219 1.2× 18 1.8k
Robert N. Taub United States 27 684 0.7× 722 0.9× 718 1.5× 300 1.2× 174 1.0× 79 2.3k
Shih–Fan Kuan United States 24 529 0.5× 672 0.8× 800 1.6× 391 1.5× 269 1.5× 46 2.1k
Paolo Muto Italy 21 664 0.7× 789 0.9× 387 0.8× 277 1.1× 192 1.0× 117 1.7k
M. A. Burgess United States 25 794 0.8× 1.1k 1.4× 451 0.9× 327 1.3× 198 1.1× 61 2.2k
Masaki Tomita Japan 25 589 0.6× 908 1.1× 527 1.1× 273 1.1× 167 0.9× 119 2.0k
Pablo J. Cagnoni United States 25 830 0.8× 1.2k 1.5× 412 0.8× 104 0.4× 289 1.6× 51 2.5k

Countries citing papers authored by Michael Kraut

Since Specialization
Citations

This map shows the geographic impact of Michael Kraut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kraut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kraut more than expected).

Fields of papers citing papers by Michael Kraut

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kraut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kraut. The network helps show where Michael Kraut may publish in the future.

Co-authorship network of co-authors of Michael Kraut

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Kraut. A scholar is included among the top collaborators of Michael Kraut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Kraut. Michael Kraut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Theis, Heidi, Michael Kraut, Marc Beyer, et al.. (2024). Cost-Efficient Transcriptomic-Based Drug Screening. Journal of Visualized Experiments. 2 indexed citations
2.
Schmidt, Susanne V., Wolfgang Krebs, Thomas Ulas, et al.. (2016). The transcriptional regulator network of human inflammatory macrophages is defined by open chromatin. Cell Research. 26(2). 151–170. 60 indexed citations
3.
Krebs, Wolfgang, Susanne V. Schmidt, Alon Goren, et al.. (2014). Optimization of transcription factor binding map accuracy utilizing knockout-mouse models. Nucleic Acids Research. 42(21). 13051–13060. 18 indexed citations
4.
Kernstine, Kemp H., James Moon, Michael Kraut, et al.. (2014). Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220. The Annals of Thoracic Surgery. 98(2). 402–410. 27 indexed citations
5.
Edelman, Martin J., Wael A. Harb, Ralph V. Boccia, et al.. (2012). Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung. Journal of Thoracic Oncology. 7(10). 1618–1621. 33 indexed citations
6.
Schneider, Bryan J., Francis P. Worden, Shirish M. Gadgeel, et al.. (2009). Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Investigational New Drugs. 27(6). 571–578. 31 indexed citations
7.
Schneider, Bryan J., Gregory P. Kalemkerian, Michael Kraut, et al.. (2008). Phase II Study of Celecoxib and Docetaxel in Non-small Cell Lung Cancer (NSCLC) Patients with Progression after Platinum-Based Therapy. Journal of Thoracic Oncology. 3(12). 1454–1459. 21 indexed citations
8.
Wozniak, Antoinette J., Lance K. Heilbrun, Ömer Küçük, et al.. (2007). Mature Results of a Phase II Trial of Gemcitabine/Paclitaxel Given Every 2 Weeks in Patients with Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 8(5). 313–318. 3 indexed citations
9.
West, Howard, John J. Crowley, Ralph Vance, et al.. (2005). Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Annals of Oncology. 16(7). 1076–1080. 54 indexed citations
10.
Vallières, Eric, Michael Kraut, & Charles R. Thomas. (2003). Pancoast (superior sulcus) neoplasms. Current Problems in Cancer. 27(2). 81–104. 11 indexed citations
11.
Rusch, Valerie W., Dorothy J. Giroux, Michael Kraut, et al.. (2001). Induction chemoradiation and surgical resection for non–small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). Journal of Thoracic and Cardiovascular Surgery. 121(3). 472–483. 187 indexed citations
12.
Kalemkerian, Gregory P., et al.. (2001). A Phase II Study of Weekly Alternating Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Cancer Investigation. 19(3). 234–238. 1 indexed citations
13.
Kraut, Michael, et al.. (2000). A Phase II Study of Mitomycin C, Etoposide, and Cisplatin in Advanced Non-Small Cell Lung Cancer. Cancer Investigation. 18(1). 1–5. 9 indexed citations
14.
Krug, Lee M., V. A. Miller, Gregory P. Kalemkerian, et al.. (2000). Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Annals of Oncology. 11(2). 227–228. 53 indexed citations
15.
Sandler, Alan B., Hedy L. Kindler, L H Einhorn, et al.. (2000). Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Annals of Oncology. 11(9). 1161–1164. 22 indexed citations
16.
Ellis, Georgiana K., Stephanie Green, Robert B. Livingston, et al.. (1999). ‘Neo-FAC’ (5-Fluorouracil, Doxorubicin, and Cyclophosphamide) for Poor-Prognosis Stage IV Breast Cancer. American Journal of Clinical Oncology. 22(5). 446–446. 1 indexed citations
17.
18.
Lian, Fangru, et al.. (1998). Genistein‐induced G2‐m arrest, P21WAF1upregulation, and apoptosis in a non‐small‐cell lung cancer cell line. Nutrition and Cancer. 31(3). 184–191. 111 indexed citations
19.
Visscher, Daniel W., et al.. (1997). Clinicopathologic Analysis of k-ras, p53, and ERBB-2 Gene Alterations in Pulmonary Adenocarcinoma. Diagnostic Molecular Pathology. 6(1). 64–64. 14 indexed citations
20.
Flaherty, Lawrence E., Antoinette J. Wozniak, Bruce G. Redman, et al.. (1991). 5-fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer. Cancer. 68(5). 944–947. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Maestre Breakdown of academic impact, for papers by Hiroyuki Yamaguchi Breakdown of academic impact, for papers by Makoto Kodaira Breakdown of academic impact, for papers by T V Colby Breakdown of academic impact, for papers by Robert N. Taub Breakdown of academic impact, for papers by Shih–Fan Kuan Breakdown of academic impact, for papers by Paolo Muto Breakdown of academic impact, for papers by M. A. Burgess Breakdown of academic impact, for papers by Masaki Tomita Breakdown of academic impact, for papers by Pablo J. Cagnoni
Rankless by CCL
2026